HansGarrincha schreef op 10 juni 2019 17:47:
JP Morgan (Obrigado: Avanti2):
Price Target: $141.00 (Dec-19)
We have updated our GLPG model for the Q1'19 results and to reflect changes in our timingassumptions for the filgotinib launches. For FY19, we make modest changes and our FY19 cash burn is now at the bottom end(prev. middle)of the guidance range (€320-340m). In addition,we push our US filgotinibRheumatoid Arthritis(RA) launchto early 2021 (prev. 2H’20), pull forward EU RA launchto 2H'20 (prev. 2021) and push out Crohn's disease(CD)and Ankylosing Spondylitis(AS) launchesby 1 year.